​

Silence Therapeutics (SLN) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

SLN Stock Forecast

Silence Therapeutics (SLN) stock forecast, based on 5 Wall Street analysts, predicts a 12-month average price target of $57.00, with a high of $67.00 and a low of $49.00. This represents a 1715.29% increase from the last price of $3.14.

- $14 $28 $42 $56 $70 High: $67 Avg: $57 Low: $49 Last Closed Price: $3.14

SLN Stock Rating

Silence Therapeutics stock's rating consensus is Buy, based on 5 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 4 Buy (80.00%), 0 Hold (0.00%), 1 Sell (20.00%), and 0 Strong Sell (0.00%).

Buy
Total 5 0 1 0 4 Strong Sell Sell Hold Buy Strong Buy

SLN Price Target Upside V Benchmarks

TypeNameUpside
StockSilence Therapeutics1715.29%
SectorHealthcare Stocks 35.94%
IndustryBiotech Stocks 83.61%

Price Target Trends

1M3M12M
# Anlaysts--2
Avg Price Target--$52.00
Last Closing Price$3.14$3.14$3.14
Upside/Downside--1556.05%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 2533--17
Mar, 2533--17
Feb, 2533---6
Jan, 2533---6
Dec, 2433---6
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jun 28, 2024Keay NakaeChardan Capital$55.00$19.00189.47%1651.59%
Jun 28, 2024Michael UlzMorgan Stanley$49.00$19.00157.89%1460.51%
Mar 13, 2024Kostas BiliourisBMO Capital$67.00$25.61161.62%2033.76%
Dec 09, 2022Morgan Stanley$18.00$15.2318.19%473.25%
Nov 17, 2022Chardan Capital$29.00$13.21119.53%823.57%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jan 29, 2025H.C. WainwrightBuyBuyhold
Dec 02, 2024BMO CapitalOutperformOutperformhold
Oct 08, 2024Morgan StanleyOverweightOverweighthold
Sep 02, 2024JefferiesBuyinitialise
Aug 16, 2024H.C. WainwrightUnderperformUnderperformhold
Aug 16, 2024BMO CapitalOutperformOutperformhold
Jun 28, 2024Morgan StanleyOverweightOverweighthold
Jun 21, 2024H.C. WainwrightBuyBuyhold
Jun 20, 2024Morgan StanleyBuyBuyhold
May 28, 2024BMO CapitalOutperformOutperformhold

Financial Forecast

EPS Forecast

Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-0.40$-0.44$-0.42$-0.39-----
Avg Forecast$-0.55$-0.82$-0.36$-0.35$-0.42$-0.45$-0.58$-0.56$-0.10
High Forecast$-0.01$-0.02$-0.02$-0.25$-0.36$-0.11$0.07$0.07$0.01
Low Forecast$-1.36$-2.03$-1.05$-0.40$-0.51$-0.68$-1.95$-1.88$-0.34
Surprise %-27.27%-46.34%16.67%11.43%-----

Revenue Forecast

$0 $100M $200M $300M $400M $500M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$5.48M$12.41M$17.50M$25.38M$43.26M----
Avg Forecast$9.10M$15.41M$23.40M$28.76M$20.74M$28.10M$17.00M$59.15M$165.82M
High Forecast$19.45M$32.92M$58.70M$41.09M$27.29M$74.44M$48.10M$167.34M$469.12M
Low Forecast$2.27M$3.84M$6.36M$18.17M$16.00M$3.64M$2.34M$8.15M$22.86M
Surprise %-39.81%-19.43%-25.21%-11.76%108.54%----

Net Income Forecast

$-250M $-190M $-130M $-70M $-10M $50M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-32.55M$-39.41M$-40.49M$-43.27M$-45.31M----
Avg Forecast$-20.38M$-30.46M$-13.20M$-39.27M$-46.69M$-50.31M$-64.15M$-62.03M$-11.27M
High Forecast$-484.09K$-723.39K$-704.41K$-27.55M$-40.55M$-11.80M$7.75M$7.49M$1.36M
Low Forecast$-50.50M$-75.47M$-39.09M$-44.84M$-56.83M$-75.46M$-216.67M$-209.52M$-38.06M
Surprise %59.67%29.38%206.68%10.18%-2.96%----

SLN Forecast FAQ

Is Silence Therapeutics stock a buy?

Silence Therapeutics stock has a consensus rating of Buy, based on 5 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 4 Buy, 0 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that Silence Therapeutics is a favorable investment for most analysts.

What is Silence Therapeutics's price target?

Silence Therapeutics's price target, set by 5 Wall Street analysts, averages $57 over the next 12 months. The price target range spans from $49 at the low end to $67 at the high end, suggesting a potential 1715.29% change from the previous closing price of $3.14.

How does Silence Therapeutics stock forecast compare to its benchmarks?

Silence Therapeutics's stock forecast shows a 1715.29% upside, outperforming the average forecast for the healthcare stocks sector (35.94%) and outperforming the biotech stocks industry (83.61%).

What is the breakdown of analyst ratings for Silence Therapeutics over the past three months?

  • April 2025: 42.86% Strong Buy, 42.86% Buy, 0% Hold, 0% Sell, 14.29% Strong Sell.
  • March 2025: 42.86% Strong Buy, 42.86% Buy, 0% Hold, 0% Sell, 14.29% Strong Sell.
  • February 2025: 50.00% Strong Buy, 50.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Silence Therapeutics’s EPS forecast?

Silence Therapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $-0.45, marking a 0% decrease from the reported $0 in 2024. Estimates for the following years are $-0.58 in 2026, $-0.56 in 2027, and $-0.1 in 2028.

What is Silence Therapeutics’s revenue forecast?

Silence Therapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $28.1M, reflecting a -35.03% decrease from the reported $43.26M in 2024. The forecast for 2026 is $17M, followed by $59.15M for 2027, and $165.82M for 2028.

What is Silence Therapeutics’s net income forecast?

Silence Therapeutics's net income forecast for the fiscal year ending in December 2025 stands at $-50.305M, representing an 11.03% increase from the reported $-45.309M in 2024. Projections indicate $-64.147M in 2026, $-62.028M in 2027, and $-11.268M in 2028.